-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
NewAmsterdam Pharma Co N.V. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to Q3 2025.
- NewAmsterdam Pharma Co N.V. Operating Income (Loss) for the quarter ending September 30, 2025 was -$55.1M, a 121% decline year-over-year.
- NewAmsterdam Pharma Co N.V. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$203M, a 10.2% decline year-over-year.
- NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2024 was -$176M, a 3.65% increase from 2023.
- NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2023 was -$183M, a 5044% decline from 2022.
- NewAmsterdam Pharma Co N.V. annual Operating Income (Loss) for 2022 was -$3.56M, a 89.8% increase from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)